Veracyte, Inc.
VCYT · Price history
Price at last available close
$50.31
+$4.23 (+9.18%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Veracyte, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services.
How they make money
Veracyte generates revenue primarily through the sale of genomic diagnostic tests and related services. In the United States, it operates a centralized laboratory model where it performs laboratory developed tests (LDTs) for clinicians, while internationally, it sells diagnostic kits and reagents to hospitals and laboratories.
Products & services
The company offers a portfolio of genomic tests including Afirma (thyroid cancer), Decipher Prostate and Decipher Bladder (urologic cancers), Prosigna (breast cancer), Percepta (lung cancer), Envisia (interstitial lung diseases), and Immunoscore (colon cancer).
Brands & revenue mix
Includes Decipher Prostate and Decipher Bladder tests.
Separate brand revenue is not available in this research.Source
Thyroid cancer diagnostic test.
Separate brand revenue is not available in this research.Source
Breast cancer diagnostic test.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Customer concentration
The company does not report significant customer concentration in its 2025 annual report, as its revenue is derived from a broad base of clinicians, hospitals, and laboratories.
Suppliers, materials & equipment
- Diagnostic kit components and reagents suppliers — The company relies on third-party suppliers for the raw materials, reagents, and components required for its diagnostic kits; specific supplier names are unnamed.Source
Business relationships & partnerships
- Thyroid Cytopathology Partners — A commercial collaboration where the partner provides initial cytopathology analysis for thyroid samples, with Veracyte performing genomic testing when results are indeterminate.Source
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
47
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
69
Fair
Financial Strength
56
Business Quality / Moat
96
Management
89
Growth Quality
48
Risk / Durability
30
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
53
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
59/100
Building Historical Record
Model Score 59/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
No strong positive signal is being highlighted from the currently available summary data.
- •M&A headline · Sep 14, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for VCYT
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can VCYT maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is VCYT's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is VCYT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What future growth or profitability would be needed to justify VCYT's current valuation?
Essential Investment Snapshot
Wall Street Score
47
Opportunity Score
53
Market Cap
$4.04B
P/E Ratio
33.9
EPS
$1.44
52-Week High
$60.91
52-Week Low
$29.45
Beta
1.95
Intrinsic Value
$55.44
Analyst Target
$55.00
Shares Outstanding
80.6M
Total Revenue
$561.9M
Total Debt
$40.1M
Dividend
No current dividend
Liquidation Value / Share
$17.23
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for VCYT
Detected from reported data — verify before acting.M&A headline · Sep 14, 2026
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on VCYT.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Veracyte Diagnostics Platform.
- +Extensive clinical utility data.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
- −Dependence on third-party suppliers for reagents and components.
- −Regulatory risks associated with CLIA-certified laboratories.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
50
Oct 1, 2026
Change
-2.8
points
Current Score
47
Oct 26, 2026
Category Changes
VCYT decreased 2.8 points because Valuation declined by 12.3 points.
Negative Contributors
- − Valuation declined by 12.3 points
Projected Score
Projected Score
52
Projected Change
+4.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Near Fair ValueCurrent Price
$50.31
Model Intrinsic Value
$55.44
Difference
−$5.13
-9.3% vs IV
Margin of Safety
9.3%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $561.9M | $517.1M | $445.8M | $361.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $156.8M | $157.1M | $147.6M | $112.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $405.1M | $360.0M | $298.1M | $248.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $93.4M | $70.8M | $69.3M | $57.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $201.6M | $210.9M | $206.0M | $184.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $309.4M | $285.9M | $282.0M | $333.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $129.8M | $89.6M | $49.2M | -$49.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $95.7M | $74.2M | $16.1M | -$85.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $2K | $15K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $108.9M | $68.2M | $25.7M | -$76.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$5.5M | $1.8M | $1.6M | -$2.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $114.5M | $66.4M | $24.1M | -$74.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $1.44 | $0.84 | $0.32 | $-1.02 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 79.66M | 78.58M | 76.48M | 72.64M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 82.23M | 80.57M | 78.16M | 72.64M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$150.3M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.31
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-20.8%
Cash Change
+36.5%
Margin Change
+17.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels, net income margin. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 15.5%. EPS declined 2580.0%. Cash increased 36.5%. Total debt declined 20.8%. Net income margin improved by 17.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?
Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?
Rumor Mill · VCYT
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial